Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.

ABSTRACT:

Objective

To compare the effectiveness and safety of three non-tumour necrosis factor (TNF) α inhibitors (rituximab, abatacept, and tocilizumab) in the treatment of rheumatoid arthritis.

Design

Population based prospective study.

Setting

53 university and 54 non-university clinical centres in France.

Participants

3162 adults (>18 years) with rheumatoid arthritis according to 1987 American College of Rheumatology criteria, enrolled in one of the three French Society of Rheumatology registries; who had no severe cardiovascular disease, active or severe infections, or severe immunodeficiency, with follow-up of at least 24 months.

Intervention

Initiation of intravenous rituximab, abatacept, or tocilizumab for rheumatoid arthritis.

Main outcome measure

SUBMITTER: Gottenberg JE 

PROVIDER: S-EPMC6344892 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature